Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS-CoV-2) is associated with a heightened risk of thrombotic events. 1 We sought to report the characteristics and thrombotic outcomes for patients with SARS-CoV-2 in an integrated healthcare system. We evaluated symptomatic patients≥ 18 years in the ambulatory setting or hospitalized at Cleveland Clinic locations in Northeast Ohio and South Florida March 13, 2020, to May 13, 2020. Each patient tested positive for a SARS-CoV-2 amplicon by reverse transcriptasepolymerase chain reaction. This study was approved by the Cleveland Clinic Institutional Review Board. Thrombotic events examined include venous thromboembolism, acute thrombotic stroke, and acute myocardial infarction. Univariable followed by multivariable regression analyses were conducted to identify predictors of thrombosis. The model included patient clinical and laboratory data. Associations were considered significant if the P value was< 0.05 (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY).

Among 3678 patients testing positive for SARS-CoV-2, 892 (24.3%) were hospitalized of which 296 (8.0%) required intensive care unit admission. Acute thrombotic events occurred in 46 (5.2%) hospitalized patients with COVID-19 comprised of venous thromboembolism in 24 (2.7%), acute ischemic stroke in 11 (1.2%), and acute myocardial infarction in 11 (1.2%) patients. For intensive care unit patients, thrombotic events occurred in 26 (8.8%), comprised of venous thromboembolism in 15 (5.1%), acute ischemic stroke in 5 (1.7%), and acute myocardial infarction in 7 (2.4%) patients (Table). Patients with SARS-CoV-2 and acute